ft 23 feb 94 smithklin confid tagamet successor sale new product smithklin beecham anglo us healthcar compani strong enough counter dramat fall sale tagamet best sell drug accord mr jan leschli incom chief execut tagamet lose us patent protect may least 10 gener version drug would launch mr leschli said yesterday concern impact tagamet patent expiri one reason compani near 5 per cent fall share price past year mr leschli quit confid sale four new drug antidepress seroxat paxil us arthriti treatment relifex relafen cancer drug kytril hepat vaccin havrix abl offset declin sale tagamet sale four new drug doubl pound 212m 1992 pound 463m last year pre tax profit 1993 rose 12 per cent pound 1 22bn top end analyst forecast turnov increas 18 per cent pound 6 16bn thank strong final quarter price pressur sever larg pharmaceut market meant trade profit margin fell 1 5 percentag point 19 1 per cent fourth quarter dividend 3 3p per share make total 10 9p 24 per cent earn climb 5 per cent 29 1p mr bob bauman leav chair british aerospac april said dividend cover reach compani target level smithklin beecham elimin year end debt first time sinc 1989 merger smithklin beckman us beecham uk net cash amount pound 38m compar pound 392m debt divis pharmaceut sale rose 21 per cent pound 3 48bn currenc factor taken growth 9 per cent rise driven sale price said mr bauman tagamet sale fell 6 per cent pound 673m currenc gain strip 15 year smithklin beckman smithklin beecham best sell product second augmentin antibiot whose sale rose 17 per cent pound 760m improv drug sale mr leschli said group prepar enter allianc us europ divis saw steadi progress sale consum healthcar includ brand soft drink ribena toothpast aquafresh rose 12 per cent pound 1 33bn lex page 22